INDEMNIFICATION AGREEMENTIndemnification Agreement • November 20th, 2020 • F-Star Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (this “Agreement”) is made and entered into this day of , 20 , by and between F-star Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • November 20th, 2020 • F-Star Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT, dated as of November 20, 2020 (this “Agreement”), is entered into by and among Spring Bank Pharmaceuticals, Inc., a Delaware corporation (the “Company”), F-Star Therapeutics Limited., a company registered in England and Wales with company number 11532458 (“F-Star”), Computershare Inc., a Delaware corporation (“Computershare”), and its wholly-owned subsidiary Computershare Trust Company, N.A., a federally chartered trust company (collectively with Computershare, the “Rights Agent”), and Martin Driscoll, acting solely in his capacity as representative of the Holders (as defined herein) (the “Holder Representative”). Capitalized terms not defined herein shall have the meanings ascribed to them in the Share Exchange Agreement (as defined below).
Private & Confidential FINAL (23 July 2020) DATED August 17, 2020 F-STAR BIOTECHNOLOGY LIMITED (1 ) and NEIL BREWIS (2 ) SERVICE AGREEMENTService Agreement • November 20th, 2020 • F-Star Therapeutics, Inc. • Pharmaceutical preparations
CONSULTING AGREEMENTConsulting Agreement • November 20th, 2020 • F-Star Therapeutics, Inc. • Pharmaceutical preparations • Massachusetts
THIS CONSULTING AGREEMENT (the “Agreement”) by and between F-star Therapeutics LLC (“Client”) and Darlene Deptula-Hicks, an individual (“Consultant”) is effective as of May 1, 2019 (the “Effective Date”).
EMPLOYMENT AGREEMENTEmployment Agreement • November 20th, 2020 • F-Star Therapeutics, Inc. • Pharmaceutical preparations • New York
This EMPLOYMENT AGREEMENT (this “Agreement”) is made and entered into effective as of July 24, 2020 (the “Effective Date”) by and between F-Star Therapeutics LLC (the “Company”), and Louis Kayitalire (the “Executive”).
